AstraZeneca’s AZD1222 Meets its Primary Endpoint in Preventing COVID-19
Shots: The Atherosclerosis Risk in Communities (ARIC) study results involves assessing of high-sensitive troponin-I blood test in 8,121 candidates with no known cardiovascular disease aged 54-73yrs. for 15yrs. The ARIC study results identified the risk of cardiac events by measuring the elevated troponin-I levels, 85% had detectable troponin, adults with high troponin-I level are twice, […]Read More
